GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » Piotroski F-Score

ObsEva (ObsEva) Piotroski F-Score : 0 (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ObsEva Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ObsEva has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for ObsEva's Piotroski F-Score or its related term are showing as below:


ObsEva Piotroski F-Score Historical Data

The historical data trend for ObsEva's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Piotroski F-Score Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 3.00 1.00 1.00 5.00 3.00

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 4.00 4.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Net Income was -11.801 + -32.798 + -12.057 + 26.777 = $-29.88 Mil.
Cash Flow from Operations was -15.251 + -10.72 + -5.096 + 7.921 = $-23.15 Mil.
Revenue was 0 + 0 + 0 + 19.637 = $19.64 Mil.
Gross Profit was 0 + 0 + 0 + 19.637 = $19.64 Mil.
Average Total Assets from the begining of this year (Dec21)
to the end of this year (Dec22) was
(64.536 + 89.144 + 54.184 + 16.807 + 16.544) / 5 = $48.243 Mil.
Total Assets at the begining of this year (Dec21) was $64.54 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $15.99 Mil.
Total Current Liabilities was $7.19 Mil.
Net Income was -20.004 + -19.144 + 0.819 + -14.65 = $-52.98 Mil.

Revenue was 0 + 0 + 0 + 22.2 = $22.20 Mil.
Gross Profit was 0 + 0 + 0 + 22.2 = $22.20 Mil.
Average Total Assets from the begining of last year (Dec20)
to the end of last year (Dec21) was
(65.447 + 101.261 + 95.182 + 97.636 + 64.536) / 5 = $84.8124 Mil.
Total Assets at the begining of last year (Dec20) was $65.45 Mil.
Long-Term Debt & Capital Lease Obligation was $13.93 Mil.
Total Current Assets was $63.42 Mil.
Total Current Liabilities was $23.51 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ObsEva's current Net Income (TTM) was -29.88. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ObsEva's current Cash Flow from Operations (TTM) was -23.15. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec21)
=-29.879/64.536
=-0.4629819

ROA (Last Year)=Net Income/Total Assets (Dec20)
=-52.979/65.447
=-0.80949471

ObsEva's return on assets of this year was -0.4629819. ObsEva's return on assets of last year was -0.80949471. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ObsEva's current Net Income (TTM) was -29.88. ObsEva's current Cash Flow from Operations (TTM) was -23.15. ==> -23.15 > -29.88 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0/48.243
=0

Gearing (Last Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=13.932/84.8124
=0.16426843

ObsEva's gearing of this year was 0. ObsEva's gearing of last year was 0.16426843. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec22)=Total Current Assets/Total Current Liabilities
=15.993/7.186
=2.22557751

Current Ratio (Last Year: Dec21)=Total Current Assets/Total Current Liabilities
=63.416/23.507
=2.69774961

ObsEva's current ratio of this year was 2.22557751. ObsEva's current ratio of last year was 2.69774961. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ObsEva's number of shares in issue this year was 107.707. ObsEva's number of shares in issue last year was 79.955. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=19.637/19.637
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=22.2/22.2
=1

ObsEva's gross margin of this year was 1. ObsEva's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec21)
=19.637/64.536
=0.30427978

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec20)
=22.2/65.447
=0.33920577

ObsEva's asset turnover of this year was 0.30427978. ObsEva's asset turnover of last year was 0.33920577. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ObsEva has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

ObsEva  (GREY:OBSEF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ObsEva Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ObsEva's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (ObsEva) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
Executives
William Michael Brown officer: Chief Financial Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan director, officer: Chief Executive Officer 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye director C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228